View Older Stories View More Recent Stories

Sep 26, 2016 09:00AM AbbVie Showcases Commitment to Research and Innovation in Dermatology at the 25th European Academy of Dermatology and Venereology Congress
Sep 26, 2016 07:00AM AbbVie Announces Submission of a Supplemental New Drug Application for Ibrutinib (IMBRUVICA®) for Treatment of Marginal Zone Lymphoma
Sep 23, 2016 05:59AM AbbVie (ABBV) Presents VIEKIRAX + EXVIERA Phase 3 Data in HCV; Sustained Virologic Response Rates Noted
Sep 23, 2016 04:00AM AbbVie Presents Data on Eight-Week Treatment of VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) in Patients with Genotype 1b Chronic Hepatitis C
Sep 20, 2016 03:48AM Karolinska Development portfolio company BioArctic enters into Collaboration with AbbVie for Parkinson's Disease Research
Sep 20, 2016 02:13AM BioArctic AB: BioArctic Enters into Collaboration with AbbVie for Parkinson’s Disease Research
Sep 15, 2016 07:33AM Biogen (BIIB), AbbVie (ABBV) Announce Significant ZINBRYTA Data in NEDA vs AVONEX
Sep 15, 2016 07:30AM New Data Presented at ECTRIMS Reinforce Efficacy of ZINBRYTA™ (Daclizumab) and Support Long-Term Safety Profile
Sep 9, 2016 11:54AM AbbVie Declares Quarterly Dividend
Sep 9, 2016 11:54AM AbbVie Declares Quarterly Dividend
Aug 30, 2016 08:00AM AbbVie to Present at the Morgan Stanley Global Healthcare Conference
Aug 30, 2016 08:00AM AbbVie to Present at the Morgan Stanley Global Healthcare Conference
Jul 29, 2016 07:38AM AbbVie Reports Second-Quarter 2016 Financial Results
Jul 28, 2016 05:32PM AbbVie (ABBV) Initiates Phase 3 Study of Venetoclax in Patients with Relapsed or Refractory
Jul 28, 2016 05:30PM AbbVie Announces Initiation of Phase 3 Study of Venetoclax in Patients with Relapsed or Refractory Multiple Myeloma
Jul 25, 2016 05:06PM AbbVie's (ABBV) VIEKIRA XR NDA Approved by U.S. FDA
Jul 25, 2016 05:04PM AbbVie Receives U.S. FDA Approval of Once-Daily VIEKIRA XR™ (dasabuvir, ombitasvir, paritaprevir and ritonavir) for the Treatment of Genotype 1 Chronic Hepatitis C
Jul 25, 2016 07:00AM AbbVie (ABBV), Bristol-Myers Squibb (BMY) to Collaborate on Rova-T + Opdivo Combo
Jul 25, 2016 06:59AM AbbVie and Bristol-Myers Squibb Announce Oncology Clinical Collaboration to Evaluate the Combination of Rova-T plus Opdivo and Opdivo + Yervoy Regimen
Jul 25, 2016 06:59AM AbbVie and Bristol-Myers Squibb Announce Oncology Clinical Collaboration to Evaluate the Combination of Rova-T plus Opdivo and Opdivo + Yervoy Regimen
Jul 25, 2016 06:18AM AbbVie (ABBV) Receives Positive CHMP Opinion on VIEKIRAX in GT4 HCV (ENTA)
Jul 25, 2016 04:00AM CHMP Grants Positive Opinion for Shorter Treatment Duration with AbbVie's VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) for Patients with Genotype 4 Chronic Hepatitis C with Compensated Cirrh
Jul 11, 2016 08:00AM AbbVie's (ABBV) ABT-414 Granted FDA Rare Pediatric Disease Designation as DIPG Treatment
Jul 11, 2016 08:00AM AbbVie Receives U.S. FDA Rare Pediatric Disease Designation for Investigational ABT-414 for the Treatment of a Type of Pediatric Brain Tumor known as Diffuse Intrinsic Pontine Glioma (DIPG)
Jul 7, 2016 06:27AM AbbVie (ABBV) to Present Positive HUMIRA Phase 3 Data in Moderate to Severe Fingernail Psoriasis
Jul 7, 2016 03:00AM AbbVie Presents Initial Data from Pivotal Phase-3 Trial Evaluating the Efficacy and Safety of HUMIRA® (adalimumab) for Moderate to Severe Fingernail Psoriasis in Adult Patients at Psoriasis 2016 Cong
Jul 5, 2016 08:04AM Biogen (BIIB), AbbVie (ABBV) Receive Marketing Approval in Europe for ZINBRYTA as MS Treatment
Jul 5, 2016 08:00AM Biogen and AbbVie’s Once-Monthly ZINBRYTA™ (Daclizumab) Approved in European Union for Treatment of Multiple Sclerosis
Jul 1, 2016 08:00AM AbbVie to Host Second-Quarter Earnings Conference Call
Jul 1, 2016 06:13AM AbbVie's (ABBV) HUMIRA Receives FDA Approval as Non-Infectious Intermediate, Posterior and Panuveitis Treatment
Jun 30, 2016 08:26PM AbbVie's HUMIRA® (adalimumab) Receives U.S. Food and Drug Administration Approval to Treat Adults with Non-Infectious Intermediate, Posterior and Panuveitis
Jun 29, 2016 07:31AM AbbVie's (ABBV) Ibrutinib Receives Fourth FDA Breakthrough Therapy Designation
Jun 29, 2016 07:30AM AbbVie Announces Fourth Breakthrough Therapy Designation Granted by the U.S. Food and Drug Administration (FDA) for Ibrutinib (IMBRUVICA®) for Chronic Graft-Versus-Host-Disease (cGVHD), a Rare Condit
Jun 20, 2016 08:00AM AbbVie Teams Up with Leading Nonprofit Organizations to Give Back to Underserved Local Communities
Jun 16, 2016 12:54PM AbbVie Declares Quarterly Dividend
Jun 16, 2016 08:00AM AbbVie Scholarship Programs Recognize Exceptional Students Living with Chronic Inflammatory Diseases
Jun 7, 2016 09:00AM New AbbVie Global Campaign Aims to Provide Educational Resources for Millions Living with Painful, Chronic Skin Disease
Jun 6, 2016 09:03AM AbbVie (ABBV) Announces Additional Data on IMBRUVICA Phase 3 in CLL/SLL
Jun 6, 2016 09:00AM AbbVie Builds Upon Robust Body of IMBRUVICA® (ibrutinib) Data with Phase 3 Longer-Term Studies in Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Presented at the American S
Jun 6, 2016 06:26AM AbbVie (ABBV) Issues Positive Update on Rova-T as r/r SCLC Treatment
Jun 6, 2016 06:13AM AbbVie (ABBV) Announces Positive ABT-414 Phase 1 Data in Aggressive Brain Cancer
Jun 5, 2016 09:00AM AbbVie Presents Encouraging Phase 1 Data for Investigational Medicine ABT-414 as Monotherapy in Patients with an Aggressive Brain Cancer at the 2016 American Society of Clinical Oncology Annual Meetin
Jun 5, 2016 07:30AM Results of Phase 1a/1b Study of AbbVie's Investigational Medicine Rovalpituzumab Tesirine (Rova-T) Showed Overall Response Rate of 39 Percent in Pretreated Patients with Biomarker-Defined Small Cell L
Jun 3, 2016 08:12AM AbbVie (ABBV) Plans Pipeline Update at R&D Day Event; Includes IMBRUVICA, ABT-484 Data
Jun 3, 2016 08:09AM AbbVie to Highlight its Innovative Pipeline to the Investment Community
Jun 2, 2016 09:00AM AbbVie's Research and Commitment to Helping People Living with Rheumatologic Diseases Highlighted at the Annual European Congress of Rheumatology (EULAR 2016)
May 31, 2016 08:00AM AbbVie to Present at the Goldman Sachs 37th Annual Global Healthcare Conference
May 31, 2016 07:23AM Biogen (BIIB), AbbVie (ABBV) Granted FDA Approval of ZINBRYTA for MS
May 31, 2016 06:19AM AbbVie (ABBV) Receives EC Approval of IMBRUVICA as CLL Treatment
May 31, 2016 06:00AM European Commission Approves IMBRUVICA® (ibrutinib) for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia
View More Recent Stories View Older Stories